Compare CHCO & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CHCO | GENB |
|---|---|---|
| Founded | 1957 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 1995 | N/A |
| Metric | CHCO | GENB |
|---|---|---|
| Price | $145.73 | $14.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $132.50 | $23.20 |
| AVG Volume (30 Days) | 126.6K | ★ 490.7K |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.87% | N/A |
| EPS Growth | ★ 13.18 | N/A |
| EPS | ★ 4.55 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.16 | N/A |
| Revenue Next Year | $3.12 | $16.58 |
| P/E Ratio | $31.92 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $113.21 | $11.00 |
| 52 Week High | $147.58 | $18.18 |
| Indicator | CHCO | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 70.24 | 46.66 |
| Support Level | $120.29 | $11.82 |
| Resistance Level | N/A | $13.96 |
| Average True Range (ATR) | 3.34 | 0.83 |
| MACD | 0.26 | 0.06 |
| Stochastic Oscillator | 84.10 | 52.34 |
City Holding Co is a financial holding company. The company conducts its principal activities through its wholly-owned subsidiary, City National Bank of West Virginia (City National). Through the bank, it provides banking, trust and investment management, and other financial solutions through its network of banking offices located in the states of West Virginia, Virginia, southeastern Ohio, and Kentucky. It offers various products and services such as overdraft facilities, savings accounts, credit cards and debit cards, loans for various purposes, investment advisory, securities brokerage, insurance products, and others. The company's business activities are currently limited to one reportable business segment, which is community banking.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.